How to Manage Sexual Side Effects After Ovarian Cancer?
At a Glance
Sexual side effects like vaginal dryness and pain are common after ovarian cancer treatment but are highly treatable. Patients can find relief through a multimodal approach including non-hormonal moisturizers, iso-osmolar lubricants, pelvic floor physical therapy, and vaginal dilators.
In this answer
5 sections
Surviving ovarian cancer is a massive hurdle, and it can be deeply frustrating and emotionally taxing to then face severe sexual side effects. Ovarian cancer treatments—including surgery that removes the ovaries (surgical menopause) and chemotherapy—cause a sudden, steep drop in estrogen in your body. This often leads to a condition known as Genitourinary Syndrome of Menopause (GSM), which includes symptoms like vaginal dryness, thinning of the vaginal tissues (atrophy), and pain during sex (dyspareunia) [1].
While these sexual side effects can severely impact your quality of life, they are highly treatable. You can effectively manage these symptoms through a multimodal approach that includes routine use of non-hormonal moisturizers, safe lubricants, pelvic floor physical therapy, and vaginal dilators [2][3].
Restoring Moisture and Protecting Tissue
The first step in managing vaginal atrophy is keeping the tissues hydrated and protected from friction. It is important to understand the difference between moisturizers (used for ongoing tissue health) and lubricants (used specifically during sexual activity).
Vaginal Moisturizers
Non-hormonal moisturizers are considered first-line treatments for GSM symptoms [4][3]. Unlike lubricants, moisturizers are meant to be absorbed by the tissue to improve long-term elasticity and moisture.
- Products containing hyaluronic acid or polycarbophil have been shown to be highly effective at improving vaginal dryness and pain when applied two to three times per week [5][6].
- Timeline: It can take several weeks of consistent, routine use to notice a significant improvement in your daily comfort, so try to be patient with the process.
Safe Lubricants
During sexual activity, a lubricant is necessary to reduce friction, but not all lubricants are safe for atrophied tissues. Many common over-the-counter lubricants are hyperosmolal—meaning they have high concentrations of ingredients like glycerin or propylene glycol. These products can draw water out of the already dry vaginal cells, causing them to shrink, become damaged, or increase inflammation [7][8].
To protect fragile tissue, it is crucial to use iso-osmolar (or “body-similar”) lubricants that match the natural pH and osmolality of vaginal secretions, ideally under 1200 mOsm/kg [9][10]. These properly formulated products effectively relieve dryness without causing irritation or disrupting the healthy bacteria in your vagina [11][12].
- Practical Tip: Because “osmolality” is rarely printed on the label, look for products specifically marketed as “iso-osmolar,” “biomimetic,” or “pH-balanced for menopause.” Check the ingredient list and avoid anything containing glycerin, propylene glycol, or warming/tingling additives.
Pelvic Floor Physical Therapy (PFPT)
Pain during sex is incredibly common among gynecologic cancer survivors. This happens not only because the tissues are thin, but because the pelvic floor muscles respond to the trauma of surgery and chronic pain by tensing up or spasming [13][14].
Multimodal pelvic floor physical therapy (PFPT) is an evidence-based, highly effective intervention that can significantly reduce pain and improve sexual function [2][15]. A specialized physical therapist can help you learn to relax these muscles. Treatment typically involves a combination of patient education, pelvic floor exercises, and specialized manual massage [2]. Research shows that the improvements gained from PFPT are well-maintained for at least a year [16].
A specific manual therapy technique called oncological perineal massage has actually been shown to improve pain, vaginal narrowing (stenosis), and sexual function even more effectively than using a vaginal dilator alone [17].
- Practical Tip: Ask your gynecologic oncologist to refer you to a physical therapist who has specific certifications in pelvic floor rehabilitation or oncology.
Using Vaginal Dilators
Vaginal dilators are smooth, tube-shaped devices made of medical-grade silicone or plastic, available in graduated sizes. They are an established tool for gently stretching the vaginal tissues, improving elasticity, and preventing the vagina from shortening or narrowing—a condition called vaginal stenosis [18][19].
Using dilators is particularly beneficial if you have experienced tissue shrinkage from treatment or if you have involuntary muscle tension. Evidence-based protocols generally recommend using a dilator coated with a safe lubricant for 10 to 15 minutes, two to three times a week [20]. Starting with a very small, comfortable size and gradually working up helps retrain your body and nervous system to tolerate penetration without pain.
- Safety and Comfort: Always get medical clearance from your surgical team before inserting anything into your vagina to avoid disrupting healing incisions. If you already experience pain, the idea of inserting a dilator can be terrifying. It is normal to feel a sensation of stretching, mild discomfort, or notice very light spotting at first. However, you should never feel sharp or severe pain—if you do, stop immediately and consult your doctor or physical therapist.
Addressing Emotional Well-Being
Physical interventions are critical, but sexual health also has a massive psychological component. Dealing with unexpected sexual side effects can cause grief, frustration, and strain on intimate relationships. Acknowledging this emotional toll is vital. Open communication with your partner, and seeking support from a sex therapist or oncology counselor, makes this multimodal approach truly holistic and can greatly improve your overall well-being.
What About Estrogen Therapy?
While non-hormonal gels and moisturizers are the recommended starting point [3], they may not be enough for severe vaginal atrophy. Localized, low-dose vaginal estrogen (delivered as a cream, ring, or tablet) is highly effective for reversing tissue thinning.
For many ovarian cancer survivors, research suggests that low-dose vaginal estrogen is generally safe to use and carries an extremely low risk of complications [21]. However, its safety depends heavily on your specific tumor subtype and hormone-receptor status. For instance, it may be perfectly safe if you had high-grade serous carcinoma, but it could be strictly contraindicated if you had a hormone-sensitive tumor, such as low-grade serous, endometrioid, or a granulosa cell tumor. Because every cancer diagnosis is unique, this is a nuanced topic you should discuss openly with your oncology team.
Common questions in this guide
Is vaginal estrogen safe to use after ovarian cancer?
What is the difference between a vaginal moisturizer and a lubricant?
How do I choose a safe lubricant after ovarian cancer treatment?
When should I consider pelvic floor physical therapy?
How do vaginal dilators help with painful sex?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Is localized, low-dose vaginal estrogen a safe option for my specific ovarian cancer subtype and hormone-receptor status?
- 2.Can you refer me to a pelvic floor physical therapist who has specific experience working with gynecologic oncology patients?
- 3.What specific brands of iso-osmolar lubricants or hyaluronic acid moisturizers do you recommend for tissues as fragile as mine?
- 4.Is my surgical healing far enough along that it is safe for me to start using vaginal dilators or internal physical therapy?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (21)
- 1
Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.
Narutytė R, Žukienė G, Bartkevičienė D
Medicina (Kaunas, Lithuania) 2024; (60(10)) doi:10.3390/medicina60101584.
PMID: 39459371 - 2
Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study.
Cyr MP, Dumoulin C, Bessette P, et al.
Gynecologic oncology 2020; (159(3)):778-784 doi:10.1016/j.ygyno.2020.09.001.
PMID: 33010968 - 3
Genitourinary syndrome of menopause: Common problem, effective treatments.
Phillips NA, Bachmann GA
Cleveland Clinic journal of medicine 2018; (85(5)):390-398 doi:10.3949/ccjm.85a.15081.
PMID: 29733783 - 4
What should guide our patient management of vulvovaginal atrophy?
Shapiro M
Climacteric : the journal of the International Menopause Society 2019; (22(1)):38-43 doi:10.1080/13697137.2018.1527306.
PMID: 30452294 - 5
Effect of a non-hormonal vaginal moisturizer on vaginal and vulvar health in postmenopausal women with breast cancer: A randomized clinical trial.
Martin BC, VItorino CN, Souza R, et al.
Maturitas 2026; (207()):108880 doi:10.1016/j.maturitas.2026.108880.
PMID: 41719902 - 6
An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman.
Sánchez-Prieto M, Mendoza N, Chedraui P, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2025; (41(1)):2500480 doi:10.1080/09513590.2025.2500480.
PMID: 40323284 - 7
Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model.
Ayehunie S, Wang YY, Landry T, et al.
Toxicology reports 2018; (5()):134-140 doi:10.1016/j.toxrep.2017.12.011.
PMID: 29854584 - 8
Vaginal irritation testing-prospects of human organotypic vaginal tissue culture models.
Ayehunie S, Landry T, Armento A
In vitro cellular & developmental biology. Animal 2024; (60(6)):569-582 doi:10.1007/s11626-024-00907-1.
PMID: 38995526 - 9
Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N, Panay N
Climacteric : the journal of the International Menopause Society 2021; (24(1)):19-24 doi:10.1080/13697137.2020.1820478.
PMID: 32990054 - 10
A randomized trial on the effectiveness and safety of 5 water-based personal lubricants.
Palacios S, Hood S, Abakah-Phillips T, et al.
The journal of sexual medicine 2023; (20(4)):498-506 doi:10.1093/jsxmed/qdad005.
PMID: 36781402 - 11
The In Vivo Effect of Water-Based Lubricants on the Vaginal Microbiome of Women from Varying Age Groups: Exploratory Analysis of a Randomized Controlled Trial.
Freixas-Coutin JA, Seo J, Hood S, et al.
Microorganisms 2024; (12(9)) doi:10.3390/microorganisms12091917.
PMID: 39338590 - 12
Clinical and Personal Lubricants Impact the Growth of Vaginal Lactobacillus Species and Colonization of Vaginal Epithelial Cells: An in Vitro Study.
Łaniewski P, Owen KA, Khnanisho M, et al.
Sexually transmitted diseases 2021; (48(1)):63-70 doi:10.1097/OLQ.0000000000001272.
PMID: 32842049 - 13
Pelvic floor disorders in women with gynecologic malignancies: a systematic review.
Ramaseshan AS, Felton J, Roque D, et al.
International urogynecology journal 2018; (29(4)):459-476 doi:10.1007/s00192-017-3467-4.
PMID: 28929201 - 14
Vaginal symptoms in women who are affected by gynecologic cancer.
Vargas Maldonado D, Madsen AM
Current opinion in obstetrics & gynecology 2021; (33(6)):474-482 doi:10.1097/GCO.0000000000000743.
PMID: 34494971 - 15
A physical therapy program to treat late-effect vaginal stenosis in gynecological cancer survivors: An interventional study.
Nascimento FC, Sampaio IM, Nunes GS, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(12)):839 doi:10.1007/s00520-024-09053-6.
PMID: 39614914 - 16
Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: Results from a one-year follow-up mixed-method study.
Cyr MP, Dostie R, Camden C, et al.
PloS one 2022; (17(1)):e0262844 doi:10.1371/journal.pone.0262844.
PMID: 35077479 - 17
Oncological perineal massage in vaginal stenosis and dyspareunia in women with gynecological cancer: a randomized controlled trial.
Pérez-García R, Abuín-Porras V, Mínguez-Esteban I, Pecos-Martín D
Frontiers in oncology 2025; (15()):1680126 doi:10.3389/fonc.2025.1680126.
PMID: 41395600 - 18
Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial.
Martins J, Vaz AF, Grion RC, et al.
BMC cancer 2021; (21(1)):682 doi:10.1186/s12885-021-08274-w.
PMID: 34112100 - 19
Sexual Health Update in Women.
Kling JM, Saadedine M, Faubion SS, Kapoor E
Journal of women's health (2002) 2023; (32(1)):10-14 doi:10.1089/jwh.2022.0392.
PMID: 36413021 - 20
Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors.
Charatsi D, Vanakara P, Evaggelopoulou E, et al.
Medicine 2022; (101(4)):e28705 doi:10.1097/MD.0000000000028705.
PMID: 35089231 - 21
Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma.
Chambers LM, Herrmann A, Michener CM, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(4)):515-524 doi:10.1136/ijgc-2019-001034.
PMID: 32075898
This page provides information on managing sexual side effects after ovarian cancer treatment for educational purposes. Always consult your gynecologic oncologist before starting new treatments or therapies.
Get notified when new evidence is published on Ovarian Cancer.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.